Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Total revenues increased by $1.2 million, or 3.5%, to $33.9 million for the year ended December 31, 2013 compared to $32.7 million for the year ended December 31, 2012. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares after opening at $13.29 moved to $13.98 on last trade day and at the end of the day closed at $13.85. Company price to sales ratio in past twelve months was calculated as 13.84 and price to cash ratio as 3.60. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) showed a negative weekly performance of -12.23%.
Horizon Pharma, Inc. (NASDAQ:HZNP) announced that it has received notice of the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, in connection with its proposed acquisition of Vidara Therapeutics International Ltd. (“Vidara”). The waiting period was scheduled to expire on May 1, 2014. Horizon Pharma Inc. (NASDAQ:HZNP) shares advanced 7.24% in last trading session and ended the day on $13.18. HZNP return on equity ratio is recorded as -340.20% and its return on assets is -80.60%. Horizon Pharma Inc. (NASDAQ:HZNP) yearly performance is 480.62%.
TherapeuticsMD, Inc. (NYSEMKT:TXMD), a women’s healthcare company, announced on 7 April positive outcomes of a rabbit irritation study for TX 004-HR (formerly referred to as TX 12-004-HR), a rapidly acting estrogen vaginal preparation capsule (VagiCap). TherapeuticsMD Inc. (NYSEMKT:TXMD) shares moved down -1.05% in last trading session and was closed at $4.69, while trading in range of $4.64 – $5.05. TherapeuticsMD Inc. (NYSEMKT:TXMD) year to date (YTD) performance is -9.98%.
Intercept Pharmaceuticals (NASDAQ:ICPT) CFO Barbara Gayle Duncan unloaded 1,154 shares of Intercept Pharmaceuticals stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $279.00, for a total value of $321,966.00. Following the completion of the transaction, the chief financial officer now directly owns 13,510 shares of the company’s stock, valued at approximately $3,769,290. Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) weekly performance is -20.71%. On last trading day company shares ended up $237.51. Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) distance from 50-day simple moving average (SMA50) is -34.71%. Analysts mean target price for the company is $546.60.
Leave a Reply